Motley Fool Australia
  •  

    Notifications

    Scott

    Wondering where you should invest $1,000 right now?

    Scott Phillips just released his 5 best stocks to buy right now and you could grab the names of these stocks instantly!

    Learn More
  • Log Out
  • Menu
  1. Stocks
    2. /
  2. Zelira Therapeutics Ltd (ASX: ZLD)
    3. /

Zelira Therapeutics Ltd (ASX: ZLD) Share Price and News

Price

$0.39

Movement

0.02 (-4.88%)

As at 15 Apr - Closed (20 mins delayed)

52 Week Range

$0.28 - $1.09

 
1 Year Return

-45.07%

Zelira Therapeutics Ltd Chart and Price Data

2025
2025
2025
2025
$0.00
$0.50
$1.00
$0.00
$0.50
$1.00
$0.00
$0.50
$1.00
$0.00
$0.50
$1.00

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $4.88 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 11.90 million
Earnings per share -0.417
Dividend per share N/A
Year To Date Return -24.19%
Earnings Yield N/A
Franking -
Earnings Yield

N/A

Franking

-

Dividend per share

N/A

Year To Date Return

-24.19%

Shares Outstanding

11.90 million

Earnings per share

-0.417

Share Price

$0.39

Day Change

0.02 (-4.88%)

52 Week Range

$0.28 - $1.09

Yesterday's Close

$0.41

Today's Open

$0.40

Days Range

$0.39 - $0.40

Volume

4,165

Avg. Volume (1 month)

2,265

Turnover

$1,639

As at 15 Apr - Closed

Zelira Therapeutics Ltd (ASX: ZLD)
Latest News

Lab worker puts hands in the air and dances around
Healthcare Shares

Guess which obscure ASX healthcare share just exploded 220% on HUGE news

| Sebastian Bowen

This ASX share has just tripled its investors' money.

Read more »

The sunset silhouette of a person leaping in the air as a large bird flies over head.
Cannabis Shares

Off and racing: Zelira shares fly 37% higher on Thursday

| Brooke Cooper

The stock has gained a whopping 111% so far this week.

Read more »

An older man throws his hands up in excitement as he rides a carnival swing high up in the air.
Share Gainers

Why has this ASX medicinal cannabis share soared 49% in two days?

| Monica O'Shea

German federal regulatory approval seems to have pleased investors.

Read more »

a medical person in white coat, gloves and protective eyewear uses tools and a test tube to put cannabis buds into the tube for research purposes.
Share Market News

Zelira shares rocket 28% before being placed on ice. Here's the latest.

| Aaron Teboneras

Zelira shareholders will have to wait until Thursday to find out the company's latest results from the German regulator.

Read more »

little green pharma share price represented by cannabis leaf character jumping cheerfully
Cannabis Shares

Blazing it? How the top ASX cannabis shares performed in FY21

| Sebastian Bowen

How did ASX cannabis shares fare in FY21?

Read more »

ASX Cannabis share price represented by asx investor holding card with cannabis leaf on it
Cannabis Shares

Why the Zelira (ASX:ZLD) share price is storming 7% higher

| Aaron Teboneras

The Zelira Therapeutics Ltd (ASX: ZLD) share price is firmly in the green today following a positive update for its…

Read more »

A white cannabis leaf set against a green background with a graph going up, indicating a rising share price for ASX cannabis shares
Cannabis Shares

Zelira (ASX:ZLD) share price falls despite strong trading update

| Aaron Teboneras

The Zelira Therapeutics Ltd (ASX: ZLD) share price is sliding despite announcing a positive trading update. Here's what the company…

Read more »

Share Market News

What will Elite Cannabinoids mean for ASX cannabis shares?

| Mitchell Lawler

Private cannabis company Elite Cannabinoids has received approval for cultivation in Western Australia. What about ASX cannabis shares?

Read more »

various forms of medicinal cannabis
Cannabis Shares

CBD to be sold in pharmacies, ASX cannabis shares react

| Kate O'Brien

Last week, it became legal to sell cannabidiol (CBD) products in chemists and pharmacies. We take a look at the…

Read more »

cannabis leaves on a rising line graph representing growth of ASX cannabis share price
Share Market News

The sector that'll grow 480% this year, expert says

| Tony Yoo

Can you smell that? That's the fragrance of a booming industry, which is still in a startup phase in Australia.

Read more »

Best Shares

5 top ASX cannabis shares in 2020

| Kate O'Brien

We take a closer look at the 5 top ASX cannabis shares in 2020 and how they delivered for shareholders…

Read more »

man walking up line graph, into clouds, representing asx shares at an all time high
Share Market News

Here's why the Zelira (ASX:ZLD) share price just rocketed to a new high

| Aaron Teboneras

The Zelira Therapeutics Ltd (ASX: ZLD) share price is rocketing higher today after announcing a new licencing agreement with Alternative…

Read more »

ZLD ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
3rd Apr 2025 2025-04-03T08:17:58 Investor PresentationYesNo8:17am1914M
1st Apr 2025 2025-04-01T17:49:02 Application for quotation of securities - ZLDYesNo5:49pm616k
31st Mar 2025 2025-03-31T13:07:09 Cleansing ProspectusYesNo1:07pm28445k
31st Mar 2025 2025-03-31T12:33:09 Proposed issue of securities - ZLDYesNo12:33pm516k
31st Mar 2025 2025-03-31T08:18:48 Zelira secures $1 Million At-the-Market Funding FacilityYesNo8:18am42M
26th Feb 2025 2025-02-26T20:14:22 Appendix 4D & FY25 Interim Financial ReportYesNo8:14pm293.6M
18th Feb 2025 2025-02-18T13:32:42 Zelira receives $1,153,000 R&D Tax Incentive Scheme RefundYesNo1:32pm21.4M
30th Jan 2025 2025-01-30T14:08:03 Quarterly Activities/Appendix 4C Cash Flow ReportYesNo2:08pm91.9M
28th Jan 2025 2025-01-28T08:25:39 Zeliras HOPE SPV Secures US$681,000 Fourth Funding TrancheYesNo8:25am21.6M
20th Jan 2025 2025-01-20T20:13:08 Change of Director's Interest Notice x 2YesNo8:13pm5233k

About Zelira Therapeutics Ltd

Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.

ZLD Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
11 Apr 2025 $0.47 $0.00 0.00% 1,156 $0.47 $0.47 $0.47
10 Apr 2025 $0.47 $0.00 0.00% 1,231 $0.51 $0.51 $0.47
09 Apr 2025 $0.47 $-0.03 -6.00% 2,108 $0.50 $0.50 $0.47
08 Apr 2025 $0.50 $0.04 8.70% 4,060 $0.46 $0.50 $0.46
07 Apr 2025 $0.46 $-0.02 -4.17% 654 $0.48 $0.48 $0.46
04 Apr 2025 $0.48 $0.00 0.00% 6,233 $0.48 $0.51 $0.48
03 Apr 2025 $0.48 $0.00 0.00% 10,577 $0.48 $0.50 $0.48
02 Apr 2025 $0.48 $0.00 0.00% 999 $0.48 $0.48 $0.48
01 Apr 2025 $0.48 $0.02 4.35% 4,688 $0.48 $0.50 $0.48
31 Mar 2025 $0.46 $-0.02 -4.17% 408 $0.48 $0.48 $0.46
28 Mar 2025 $0.48 $0.00 0.00% 1,589 $0.50 $0.50 $0.48
27 Mar 2025 $0.48 $0.00 0.00% 4,148 $0.48 $0.50 $0.48
26 Mar 2025 $0.48 $0.01 2.13% 560 $0.48 $0.48 $0.48
25 Mar 2025 $0.47 $0.00 0.00% 58 $0.47 $0.47 $0.47
24 Mar 2025 $0.47 $0.00 0.00% 130 $0.47 $0.47 $0.47
21 Mar 2025 $0.47 $0.00 0.00% 210 $0.47 $0.47 $0.47
20 Mar 2025 $0.47 $0.00 0.00% 131 $0.47 $0.47 $0.47
19 Mar 2025 $0.47 $0.00 0.00% 2,107 $0.47 $0.47 $0.47
18 Mar 2025 $0.47 $-0.01 -2.08% 512 $0.48 $0.49 $0.47
17 Mar 2025 $0.48 $0.00 0.00% 72 $0.48 $0.48 $0.48

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
17 Jan 2025 Oludare Odumosu Expiry 110,334 $69,510
As advised by the company. Lapsed because conditions have not been met.
As per announcement on 20/01/2025
17 Jan 2025 Osagie Imasogie Expiry 335,094 $211,109
As advised by the company. Lapsed because conditions have not been met.
13 Dec 2024 Osagie Imasogie Issued 3,500,000 $1,400,000
As advised by the company. USD,3,500,000 Convertible Notes, Issue

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Timothy (Tim) Ryan Slate Company SecretaryNon-Executive Director Dec 2016
Mr Slate provides accounting and secretarial advice to private and public companies. Mr Slate has over 15 years of experience in chartered accounting.
Dr Oludare Odumosu Managing Director Dec 2019
Dr Odumosu has over 10 years of experience in corporate pharmaceutical business development, strategy & operational leadership including alliance management, Dr. Odumosu brings a unique combination of experiences from several academic, public health and life science organisations.
Mr Osagie Imasogie Non-Executive ChairmanNon-Executive Director Dec 2019
Mr Imasogie has over 30 years of experience in the fields of law, finance, business management, healthcare and the pharmaceutical industry. He is a co-founder and the Senior Managing Partner of PIPV Capital, a Private Equity Firm that is focused on the Life Sciences vertical. Prior to co-founding PIPV Capital, Osagie conceptualised and established GlaxoSmithKline Ventures and was its founding Vice President.
Mr Greg Blake Executive Director Feb 2023
Mr Blake has led the strategic development and commercialisation of a number of products across a range of therapeutic categories. Throughout his near 20 years working in healthcare Greg has built a solid foundation of knowledge across marketing and the entire commercial value chain.
Dr Donna Gentile O'Donnell Non-Executive Director Jun 2023
Dr O'Donnell has led a diverse and successful career in health care, life sciences and public service concentrated in the Greater Philadelphia area. Donna was formerly a principal with O'Donnell Associates, her clients included non-profit organisations, universities, and life science companies, including Cephalon Pharmaceuticals.

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Mr Malik Majeed 1,134,644 10.00%
Quincy Street Capital Llc 456,622 4.02%
Sharri J Rochlin <Rochlin Family Resource A/C> 393,168 3.46%
Mr Zoltan Kerekes 393,168 3.46%
Osagie Imasogie 393,168 3.46%
Sunset Capital Management Pty Ltd <Sunset Superfund A/C> 383,725 3.38%
Ms Lisa Gray 381,988 3.37%
Mera I Llc\C 332,479 2.93%
Muller Ct Pty Ltd <Muller Super Fund A/C> 312,126 2.75%
Mr Torsten M Geers <The Torsten M Geers Living A/C> 307,454 2.71%
Mr Steve Shapiro 302,571 2.67%
Mara Gordon 252,242 2.22%
Mr Saul Shorr and Mrs Margaret Shorr 151,285 1.33%
Dr Chanda Latrice Macias 146,479 1.29%
Mera Ii Llc\C 133,372 1.18%
Oludare Odumosu 131,766 1.16%
Citicorp Nominees Pty Limited 128,727 1.13%
Mr Daniel Hexter and Mrs Shannon Hexter 103,389 0.91%
Geers Egag Llc 85,715 0.76%
Connie H Katz and Samuel P Katz 78,063 0.69%

Profile

since

Note